2022

1. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

   Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953